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A non-TBI based preparative regimen, Bu/Mel/ATG was stud- 
ied in the setting of UCBT. Children with infant ALL and older 
patients (pts) unable to tolerate TBI or with high risk/refractory 
leukemia were enrolled, n=38. Indications for transplant were 15 
AML, 17 ALL, 1 undifferentiated leukemia, 2 JMML,  and 3 
MDS; most pts had high risk disease. Donor/ rec ip ient  HLA 
matching was 5 or 6/6 (n=21) or 4/6 (n=17) by low resolution 
molecular typing for I-{LA A, B, and high resolution (HR) DRB1 
typing. However by HR class I typing, 6 pts received 3/6 or less 
matched units. Bu was given on d -8 through d -5 either orally (1 
mg/kg) or by W (Busulfex 1 mg/kg if age _<4 yrs or 0.8 mg/kg if 
age>4 yrs) q 6 h x 16 doses. Bu doses were adjusted to target Css 
600 - 900 ng/mL. Me1 (45 mg'/m 2 x3 doses on d -4  through d -2). 
ATG (30 mg/kg/day) was given on d -3 through d -1. GVHD 
prophyla~s was cyclosporine and steroids. The median age was 
2.0 yrs (range 0.5-17.3 yrs) and median wt was 10.9 kg (range 4.5- 
90.0 kg). The cord blood infusion had a median 9.7 x 107nucleated 
cells/kg (range 1.4 to 27.7) with a median 2.6 x I05 CD34+ 
cells/kg (range 0.2 to 9.5, n=31), precryoprese~wation. By d +42 
post transplant 16/38 pts had not achieved ANC>500/mm 3.How- 
ever, 3 patients engrafted on days +44, +49, +53; 3 had early 
relapse and 7 expired due to transplant related mortality prior to 
day +42. The cumulative incidence (CINC) of ANC>500/mm 3 
was 0.66 (95% CI 0.53, 0.82). In pts achieving ANC>500, the 
median time to recovery was 27 d (range 1i to 53 d). The CINC 
of platelets > 20K was 0.52 (95% CI 0.34, 0.69). In pts achieving 
pits > 20K, the median time to recovery was 64 d (range 30 to 272 
d). Gr I I I/ IV aGVHD was seen in 11 (29%). CGVHD occurred 
in 4/20 (limited 3) pts who smwived >100 d. VOD occurred in 3 
pts(1 fatal). Failure after d +I00 was due to relapse (3), nonen- 
graftnaent (1), and cGVHD (1). The non-relapse mortality at 180 
d was 0.35 (95% CI 0.19, 0.50). With a median f/u of 7.8 mos (2.5 
- 27.2 mos), the 1 yr survival probability is 0.41 (SE=0.09). Con- 
clusion: in this high risk patient cohort Bu/Mel/ATG may be suf- 
ficiently myeloablative and innnunosuppressive to allow engraft- 
ment of UCBT in pts with acute leukemia. Heavily pretreated pts 
experienced a high incidence of early infections and regimen relat- 
ed toxicity. 
54 
DONOR CD4+CD25 + REGULATORY T-CELLS, A CD4 ÷ POPULATION 
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Bone marrow transplantation (BMT) is a potentially curative 
treannent for many diseases, but the wider use of allogeneic BMT 
is limited by the frequent and severe outcome of graft vs. host dis- 
ease (GVHD). Unfortunately, efforts to reduce GVHD by remov- 
ing donor T-cells from the graft have resulted in poor engraft- 
ment and elevated isease recurrence. Alternative cell populations 
capable of supporting allogeneic hematopoietic stem/progenitor 
cell (HSPC) engraftment without inducing GVHD could increase 
the use of this treatment while broadening the pool of acceptable 
donors. Mthough unfractionated CD4 + T-cells have not been 
shown to be an efficient facilitating population, we investigated 
the capacity of the CD4+CD25 + regulatory (T-reg) subset o sup- 
port donor HSPC engraftment.  In a murine allogeneic mis- 
matched model of 1-2x106 C57BL/6 (B6) T-cell depleted bone 
marrow cells (BM-TCD) transplanted into 7.0 Gy sublethally 
irradiated BALB/c recipients, donor B6 T-regs (lxl06) injected 
with BM-TCD supported significantly greater IL-3 responsive 
donor progenitor colonies one week after transplant and signifi- 
cantly increased donor chimerism in the blood, bone marrow, 
lymph nodes, and spleen one month after transplant. In contrast 
to BM-TCD supplemented with either CD25 depleted T-cells or 
highly enriched CD4+CD25 - T-cells, transplantation f allogeneic 
T - reg  supplemented marrow did not result in GVHD.  In 
immunological analyses 3-4 months post-BMT, chimeric recipi- 
ents transplanted with T-regs did not generate killing against H- 
2 t' (donor) or H-2 d (host) targets. However, recipients of only 
BM-TCD that rejected the donor graft did generate anti-H-26 
killing. Cells from T-reg recipients exhibited normal proliferation 
in response to LPS or anti-CD3 mAb. Furthermore, injection of 
T-reg recipients with allogeneic H-2 k cells resulted in a primed 
anti H-2 k CTL response. These results indicate that a CD4 + T-  
cell population is capable of increasing donor engraftment without 
inducing GVHD. Importantly, T-reg recipients do not appear to 
be immunologically impaired, but may be specifically tolerant o 
donor and host cells. CD4+CD25 ÷ T-cells may thus provide a use- 
ful alternative to unfractionated T-cells for supporting engraft- 
ment during non-myeloablative BMT. 
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Allogeneic transplantation is a potentially curative treatment for 
hematologic malignancies but is associated with a high rate of 
complications. Busulfan is a common component of pretransplant 
conditioning but has an erratic and unpredictable bioavailability 
when administered orally. Intravenous busulfan was recently 
introduced into clinical practice. Prior studies showed consistent 
and predictable drug delivery with tight control of bnsulfan plas- 
ma levels avoiding over and under-dosing.  Th is  study was 
designed to define the role of intravenous busulfan in different 
transplant and disease settings. It included 45 patients with various 
hematologic malignancies conditioned with high-dose intravenous 
busulfan containing regimens prior to allogeneic transplantation. 
The donors were HLA-matched siblings (n=24), matched unrelat- 
ed (n=15) or 1-antigen mismatched related donors (n=6). Forty- 
four patients had initial engraftment. The toxicity profile was 
favorable. No patient developed VOD. Acute GVHD grade II-IV 
occurred in 18 patients (40%). Six patients died of treatment- 
related causes, five of complications related to acute GVHD and 
only one died of organ toxicity. Actuarial non-relapse-related 
mortality risk was 10% at day 100 and 17% at 2 years post-trans- 
plant. The actuarial 2-year OS and DFS rates are 62% and 44%, 
respectively. Disease status other than refractory relapse, myeloid 
disease, and no severe GVHD post-transplant predicted for 
longer DFS in a multivariant model. Intravenous busulfan con- 
taining regimens allows consistent engraftment of allografts from 
related and unrelated onors such that myeloablation is adminis- 
tered with a toxicity profile typical of non-myeloablative condi- 
tioning. Favorable outcome was seen in patients with myeloid 
leukemias and in early or intermediately advanced isease however 
this regimen may not be sufficiently cytoreductive in patients with 
very advanced or active leukemia and in ALL. intravenous busul- 
fian merits further studies to better define its role as a preferred 
substitute for oral busulfan in pretransplant conditioning. 
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